Myelopathy from Waldenström macroglobulinemia: Improvement after Rituximab therapy

Bernardo Liberato, Adrienne Riethmuller, Raymond L. Comenzo, Eric Lis, Jeffrey J. Raizer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

Original languageEnglish (US)
Pages (from-to)207-211
Number of pages5
JournalJournal of Neuro-Oncology
Issue number2
StatePublished - Jun 1 2003


  • Myelopathy
  • Rituximab
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Myelopathy from Waldenström macroglobulinemia: Improvement after Rituximab therapy'. Together they form a unique fingerprint.

Cite this